U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
139594
Substance Class Protein
Created
by admin
on Sat Dec 16 05:50:59 GMT 2023
Edited
by admin
on Sat Dec 16 05:50:59 GMT 2023
Protein Type ENZYME
Protein Sub Type CYTOCHROME P450
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
L9DP834D1P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYTOCHROME P450 2C9
Common Name English
CYP2C9
Common Name English
CYTOCHROME P 450 MP-4
Common Name English
CYTOCHROME P 450 2C9
Common Name English
HUMAN CYTOCHROME P450 2C9
Common Name English
S-MEPHENYTOIN 4-HYDROXYLASE
Common Name English
LIMONENE 6-MONOOXYGENASE
Common Name English
Code System Code Type Description
FDA UNII
L9DP834D1P
Created by admin on Sat Dec 16 05:51:07 GMT 2023 , Edited by admin on Sat Dec 16 05:51:07 GMT 2023
PRIMARY
UNIPROT
P11712
Created by admin on Sat Dec 16 05:51:07 GMT 2023 , Edited by admin on Sat Dec 16 05:51:07 GMT 2023
PRIMARY
CAS
329978-01-0
Created by admin on Sat Dec 16 05:51:07 GMT 2023 , Edited by admin on Sat Dec 16 05:51:07 GMT 2023
PRIMARY
Related Record Type Details
Structure of Orbitazine
SUBSTRATE -> METABOLIC ENZYME
Structure of ETRAVIRINE
SUBSTRATE -> METABOLIC ENZYME
Structure of CERITINIB
INHIBITOR -> METABOLIC ENZYME
ceritinib also inhibits CYP2C9 in vitro.
Structure of DRONABINOL
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of CARVEDILOL
SUBSTRATE -> METABOLIC ENZYME
Structure of ACT-333679
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of TRIFAROTENE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of MOMELOTINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of OTESECONAZOLE
INDUCER -> METABOLIC ENZYME
mRNA levels in at least 2 hepatocyte cultures. Up 10 micromolar OTESECONAZOLE
Structure of PRALSETINIB
INDUCER -> METABOLIC ENZYME
Structure of NE-100 FREE BASE
SUBSTRATE -> METABOLIC ENZYME
Structure of BREXPIPRAZOLE
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of MECLIZINE
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of 1-(((4-((7-METHOXY-6-(SULFOOXY)-4-QUINOLINYL)OXY)PHENYL)AMINO)CARBONYL)CYCLOPROPANECARBOXYLIC ACID
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of WARFARIN, (S)-
SUBSTRATE -> METABOLIC ENZYME
Structure of VORICONAZOLE
SUBSTRATE -> METABOLIC ENZYME
IN VITRO
Structure of RUCAPARIB
INHIBITOR -> METABOLIC ENZYME
REVERSIBLE
Structure of LOSARTAN
INHIBITOR -> METABOLIC ENZYME
Structure of ELAGOLIX
INDUCER -> TARGET
Structure of Desloratadine
NON-INHIBITOR -> METABOLIC ENZYME
Structure of ANETHOLTRITHION
SUBSTRATE -> METABOLIC ENZYME
Structure of AVAPRITINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of RITONAVIR
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of SELADELPAR
SUBSTRATE -> METABOLIC ENZYME
Structure of ALECTINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of ENZALUTAMIDE
INDUCER -> METABOLIC ENZYME
Therefore, co-administration of enzalutamide with CYP3A4, 2C9, and 2C19 substrates with a narrow therapeutic index should be avoided.
MODERATE
Structure of SELUMETINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of LOSARTAN
SUBSTRATE -> METABOLIC ENZYME
Structure of ENCORAFENIB
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of FORMOTEROL
SUBSTRATE -> METABOLIC ENZYME
Structure of PHENOBARBITAL
INDUCER -> METABOLIC ENZYME
Structure of ALOSETRON
SUBSTRATE -> METABOLIC ENZYME
Alosetron is metabolized by human microsomal cytochrome P450 (CYP), shown in vitro to involve enzymes 2C9 (30%), 3A4 (18%), and 1A2 (10%).
MAJOR
Structure of Lifitegrast
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of TRIMETHOPRIM
SUBSTRATE -> METABOLIC ENZYME
Structure of PHENTHOATE
INHIBITOR -> METABOLIC ENZYME
CYP2C9 activity was extensively inhibited (more than 90% inhibition) by organophosphorus insecticides phenthoate
Structure of GS-563117
INHIBITOR -> METABOLIC ENZYME
Structure of VERUBECESTAT
NON-INHIBITOR -> METABOLIC ENZYME
Structure of FENITROTHION
INHIBITOR -> METABOLIC ENZYME
CYP2C9 activity was extensively inhibited (more than 90% inhibition) by organophosphorus insecticides fenitrothion
Structure of FLUOXETINE
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of FLURBIPROFEN
SUBSTRATE -> METABOLIC ENZYME
Structure of SESAMIN
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of RHINACANTHIN C
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of CLASCOTERONE
INHIBITOR -> METABOLIC ENZYME
clascoterone cream, 1%, has no clinically meaningful effect on the PK of drugs metabolized by CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 or 3A4.
IC50
Structure of RIVOCERANIB
SUBSTRATE -> METABOLIC ENZYME
Structure of RIFAMYCIN
INHIBITOR -> METABOLIC ENZYME
Rifamycin is an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5 in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose clinically relevant inhibition of these enzymes in vivo is unlikely.
Structure of LUSUTROMBOPAG
INHIBITOR -> TARGET
MINOR
Structure of FLUVOXAMINE
INHIBITOR -> METABOLIC ENZYME
Structure of ROSUVASTATIN
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of ALDUMASTAT
SUBSTRATE -> METABOLIC ENZYME
Structure of ERDAFITINIB
SUBSTRATE -> METABOLIC ENZYME
Contribution of CYP2C9 to the total clearance of erdafitinib is estimated to be 39%
Structure of ISTRADEFYLLINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of VISMODEGIB
SUBSTRATE -> METABOLIC ENZYME
Structure of LUMIRACOXIB
SUBSTRATE -> METABOLIC ENZYME
Structure of RIFAMPIN
INDUCER -> METABOLIC ENZYME
Structure of BEROTRALSTAT
INHIBITOR -> METABOLIC ENZYME
WEAK
Structure of RIMEGEPANT
SUBSTRATE -> METABOLIC ENZYME
Structure of ZIMLOVISERTIB
NON-INHIBITOR -> METABOLIC ENZYME
Structure of CANNABIDIOL
SUBSTRATE -> METABOLIC ENZYME
Structure of UPADACITINIB
INHIBITOR -> METABOLIC ENZYME
In the direct inhibition assays, upadacitinib inhibited CYP2C9 with an IC50 value of 40.3 μM
IC50
Structure of OZENOXACIN
INHIBITOR -> METABOLIC ENZYME
In vitro, ozenoxacin caused mild inhibition of CYP3A4 and CYP2C9 at high concentrations (≥100 μM).
Structure of PARATHION
SUBSTRATE -> METABOLIC ENZYME
Structure of AVATROMBOPAG
SUBSTRATE -> METABOLIC ENZYME
Structure of CYCLOPHOSPHAMIDE ANHYDROUS
SUBSTRATE -> METABOLIC ENZYME
Structure of UMBRALISIB
SUBSTRATE -> METABOLIC ENZYME
Structure of ISAVUCONAZOLE
INHIBITOR -> METABOLIC ENZYME
Structure of VALPROIC ACID
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of ETHINYL ESTRADIOL
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of AZILSARTAN
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of MEPHENYTOIN, (+)-
SUBSTRATE -> METABOLIC ENZYME
Structure of ARTEMETHER
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of FLIBANSERIN
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of RIVOGLITAZONE
SUBSTRATE -> METABOLIC ENZYME
Structure of NINGETINIB
SUBSTRATE -> METABOLIC ENZYME
NINGETINIB M1 FORMATION
MINOR
Vmax
Structure of DELAVIRDINE
INDUCER -> METABOLIC ENZYME
Structure of CARVEDILOL, (-)-
SUBSTRATE -> METABOLIC ENZYME
Structure of UAB-30
SUBSTRATE -> METABOLIC ENZYME
Structure of ERVOGASTAT
INHIBITOR -> METABOLIC ENZYME
Structure of MITAPIVAT
INDUCER -> METABOLIC ENZYME
More than two-fold increase in mRNA expression concentration dependence. Use of mitapivat should be avoided with substrates of CYP3A, CYP2B6, or CYP2C that have narrow therapeutic index.
Structure of APALUTAMIDE
INDUCER -> METABOLIC ENZYME
Structure of SELEGILINE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of DELAFLOXACIN
INDUCER -> METABOLIC ENZYME
Delafloxacin was a mild inducer (less than 2 fold) of CYP2C9 at a concentration of 100 μM
Structure of GLICLAZIDE
SUBSTRATE -> METABOLIC ENZYME
Clearance of gliclazide in CYP2C9*2 and *3 was significantly reduced compared to the wild-type.
Structure of BELINOSTAT
SUBSTRATE -> METABOLIC ENZYME
Structure of TAFENOQUINE
INHIBITOR -> METABOLIC ENZYME
Ki
Structure of BENZAMIDE, N-CYCLOPROPYL-3-(5-((2-FLUORO-4-IODOPHENYL)AMINO)-3,4,6,7-TETRAHYDRO-6,8-DIMETHYL-2,4,7-TRIOXOPYRIDO(4,3-D)PYRIMIDIN-1(2H)-YL)-
INHIBITOR -> METABOLIC ENZYME
Structure of GLIMEPIRIDE
SUBSTRATE -> METABOLIC ENZYME
Clearance of glimepiride CYP2C9*2 and *3 was significantly reduced compared to the wild-type.
Structure of TRICLABENDAZOLE SULFONE
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of ISAVUCONAZOLE
INDUCER -> METABOLIC ENZYME
Structure of BOSENTAN ANHYDROUS
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of SULFADIAZINE
SUBSTRATE -> METABOLIC ENZYME
Structure of TRICLABENDAZOLE
SUBSTRATE -> METABOLIC ENZYME
Structure of SELEXIPAG
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of MIVEBRESIB
SUBSTRATE -> METABOLIC ENZYME
Structure of VALDECOXIB
SUBSTRATE -> METABOLIC ENZYME
Structure of UMBRALISIB
INHIBITOR -> METABOLIC ENZYME
Structure of REGORAFENIB ANHYDROUS
INHIBITOR -> METABOLIC ENZYME
Ki
Structure of GABAPENTIN ENACARBIL
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of ZAFIRLUKAST
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of OLODATEROL
SUBSTRATE -> METABOLIC ENZYME
Structure of SKF-26754A
INHIBITOR -> METABOLIC ENZYME
With the primary amine (SKF26754), the CYP2C9 reaction was the most inhibited.
Structure of ZOLPIDEM
SUBSTRATE -> METABOLIC ENZYME
Structure of FLUCONAZOLE
INHIBITOR -> METABOLIC ENZYME
MAJOR
Structure of TASIMELTEON
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of AMIODARONE
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of SEBETRALSTAT
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of Tuspetinib
INHIBITOR -> METABOLIC ENZYME
Structure of ETRAVIRINE
INHIBITOR -> METABOLIC ENZYME
Structure of BRIVARACETAM
SUBSTRATE -> METABOLIC ENZYME
Structure of CARVEDILOL, (+)-
SUBSTRATE -> METABOLIC ENZYME
Structure of MICONAZOLE
INHIBITOR -> METABOLIC ENZYME
Structure of OLMESARTAN
INHIBITOR -> METABOLIC ENZYME
Structure of STIRIPENTOL
INHIBITOR -> METABOLIC ENZYME
Structure of TEMSIROLIMUS
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of ENCORAFENIB
INDUCER -> METABOLIC ENZYME
IC50
Structure of VECABRUTINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of CHLORAMPHENICOL
NON-INHIBITOR -> METABOLIC ENZYME
Structure of Opnurasib
INHIBITOR -> METABOLIC ENZYME
Not time dependent
IC50
Structure of PF-06821497
NON-INHIBITOR -> METABOLIC ENZYME
Structure of PROADIFEN
INHIBITOR -> METABOLIC ENZYME
Structure of PITAVASTATIN
SUBSTRATE -> METABOLIC ENZYME
Structure of ENZALUTAMIDE
INHIBITOR -> METABOLIC ENZYME
Structure of ETORICOXIB
SUBSTRATE -> METABOLIC ENZYME
Structure of DEXIBUPROFEN
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of MAVOGLURANT
SUBSTRATE -> METABOLIC ENZYME
Structure of OSPEMIFENE
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of IBUPROFEN
SUBSTRATE -> METABOLIC ENZYME
Structure of LICOFELONE
SUBSTRATE -> METABOLIC ENZYME
Structure of ENASIDENIB
SUBSTRATE -> METABOLIC ENZYME
Structure of 1-(((4-((7-METHOXY-6-(SULFOOXY)-4-QUINOLINYL)OXY)PHENYL)AMINO)CARBONYL)CYCLOPROPANECARBOXYLIC ACID
SUBSTRATE -> METABOLIC ENZYME
Structure of ZILEUTON
SUBSTRATE -> METABOLIC ENZYME
Structure of BOCIDELPAR
INHIBITOR -> METABOLIC ENZYME
Structure of CAPSAICIN
SUBSTRATE -> METABOLIC ENZYME
Structure of PHENYTOIN
SUBSTRATE -> METABOLIC ENZYME
Structure of KB-0742
NON-INHIBITOR -> METABOLIC ENZYME
IC50
Structure of BRANEBRUTINIB
INHIBITOR -> METABOLIC ENZYME
Structure of FEBUXOSTAT
SUBSTRATE -> METABOLIC ENZYME
Structure of VERINURAD
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of PRALSETINIB
INHIBITOR -> METABOLIC ENZYME
Structure of SELICICLIB
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of TRICLABENDAZOLE SULFOXIDE
SUBSTRATE -> METABOLIC ENZYME
Structure of IMATINIB
INHIBITOR -> METABOLIC ENZYME
COMPETITIVE INHIBITOR
Ki
Structure of NAPROXEN
SUBSTRATE -> METABOLIC ENZYME
Structure of ZAFIRLUKAST
INHIBITOR -> METABOLIC ENZYME
in vitro studies utilizing human liver microsomes show that zafirlukast inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymes at concentrations close to the clinically achieved total plasma concentrations
Structure of PF-06835919
NON-INHIBITOR -> METABOLIC ENZYME
Structure of SKF-8742
INHIBITOR -> METABOLIC ENZYME
Structure of LESINURAD
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of TRAMADOL
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of OXYMETAZOLINE
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of MK-8189
NON-INHIBITOR -> METABOLIC ENZYME
Structure of OLACAFTOR
INHIBITOR -> METABOLIC ENZYME
Structure of FIDAXOMICIN
INHIBITOR -> METABOLIC ENZYME
Fidaxomicin and OP-1118 exhibited inhibitory potential for prominent intestinal CYP isoenzymes (CYP3A4, CYP2C9, and CYP2C19) in in vitro studies with human liver microsomes, based on estimated intestinal concentrations (fidaxomicin [I]2, 800 μg/mL).
IC50
Structure of GLECAPREVIR
SUBSTRATE -> METABOLIC ENZYME
Structure of METRONIDAZOLE
INHIBITOR -> METABOLIC ENZYME
POTENT
Structure of N-Desmethylclobazam
INHIBITOR -> METABOLIC ENZYME
WEAK
IC50
Structure of VORICONAZOLE
INHIBITOR -> METABOLIC ENZYME
Structure of TRICLABENDAZOLE SULFOXIDE
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of PROFENOFOS
INHIBITOR -> METABOLIC ENZYME
CYP2C9 activity was extensively inhibited (more than 90% inhibition) by organophosphorus insecticides profenofos
Structure of LONAFARNIB
SUBSTRATE -> METABOLIC ENZYME
IN VITRO
Structure of BORTEZOMIB
SUBSTRATE -> METABOLIC ENZYME
Structure of PEXIDARTINIB
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of LURASIDONE
INHIBITOR -> METABOLIC ENZYME
MODERATE
Structure of EDARAVONE
INHIBITOR -> METABOLIC ENZYME
Edaravone inhib it e d CYP2C9, BCRP, OAT3, and induced CYP1A2 in vitro.
Structure of CYCLOHEXANAMINE, N-(2-ETHOXYETHYL)-1-PHENYL-
SUBSTRATE -> METABOLIC ENZYME
Structure of METHOXYCHLOR
SUBSTRATE -> METABOLIC ENZYME
Structure of MALATHION
INHIBITOR -> METABOLIC ENZYME
CYP2C9 activity was extensively inhibited (more than 90% inhibition) by organophosphorus insecticides malathion
Structure of DIPHENHYDRAMINE
SUBSTRATE -> METABOLIC ENZYME
CYP1A2, CYP2C9, and CYP2C19 are involved in the metabolism of diphenhydramine as low-affinity P450 isozymes.
Structure of DICLOFENAC
SUBSTRATE -> METABOLIC ENZYME
Structure of CELECOXIB
SUBSTRATE -> METABOLIC ENZYME
Structure of OLICERIDINE
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of TERIFLUNOMIDE
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of SILIBININ A
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of OSPEMIFENE
SUBSTRATE -> METABOLIC ENZYME
Ospemifene is primarily metabolized by CYP3A4, 2C9, and 2C19 responsible for approximately 40 to 50%, ~25%, and ~25%, respectively, of its clearance.
MAJOR
Structure of Siponimod
SUBSTRATE -> METABOLIC ENZYME
CYP2C9 genotype had a significant effect on the exposure of siponimod, with CYP2C9 *3/*3, CYP2C9 *1/*3, and CYP2C9 *2/*3 individuals having the largest effect.
MAJOR
Structure of ATAZANAVIR
INHIBITOR -> METABOLIC ENZYME
COMPETITIVE INHIBITOR
Ki
Structure of SARIZOTAN
SUBSTRATE -> METABOLIC ENZYME
Structure of IROSUSTAT
SUBSTRATE -> METABOLIC ENZYME
Structure of VOXELOTOR
SUBSTRATE -> METABOLIC ENZYME
In vitro metabolism studies involving recombinant enzymes indicated that CYP3A4, CYP1A1, CYP3A5, CYP2C9, CYP2C19 and CYP2B6 were responsible for the oxidative metabolism of voxelotor.
Structure of SONIDEGIB
INHIBITOR -> METABOLIC ENZYME
Ki
Structure of ABROCITINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of TOLBUTAMIDE
SUBSTRATE -> METABOLIC ENZYME
Structure of AVAPRITINIB
INHIBITOR -> METABOLIC ENZYME
Structure of AVATROMBOPAG
INDUCER -> METABOLIC ENZYME
WEAK
Structure of COBICISTAT
NON-INHIBITOR -> METABOLIC ENZYME
Structure of IXAZOMIB
SUBSTRATE -> METABOLIC ENZYME
At higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms with estimated relative contributions of 3A4 (42%), 1A2 (26%), 2B6 (16%), 2C8 (6%), 2D6 (5%), 2C19 (5%) and 2C9 (< 1%).
Structure of FERROQUINE
SUBSTRATE -> METABOLIC ENZYME
HUMAN LIVER
TISSUE EXPRESSION -> PARENT
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966